Clinical trial
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
NCT01251575 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 1, 2010
- Completion date
- February 11, 2019
- Enrollment
- 77 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute lymphoblastic leukemia, adult acute myeloid leukemia, adult diffuse large b-cell lymphoma, adult myelodysplastic syndrome, adult non-hodgkin lymphoma, aggressive non-hodgkin lymphoma, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, childhood diffuse large b-cell lymphoma, childhood myelodysplastic syndrome, childhood non-hodgkin lymphoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia in remission, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, hematopoietic and lymphoid cell neoplasm, mantle cell lymphoma, plasma cell myeloma, prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent hodgkin lymphoma, refractory chronic lymphocytic leukemia, t-cell prolymphocytic leukemia, waldenstrom macroglobulinemia